To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions
For individuals with healthy GI function and no absorption issues, quality oral supplements may provide meaningful support at a fraction of the cost
The decrease in VIP distribution was proposed to be secondary to infection and inflammation
Inadequate levels of B12 can lead to conditions like megaloblastic or pernicious anemia, resulting in fatigue, weakness, and pale skin